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Abstract
Frequent hemodialysis can alter volume status, blood pressure and the concentration of 
osmotically active solutes, each of which might affect residual kidney function (RKF). In the 
Frequent Hemodialysis Network Daily and Nocturnal Trials, we examined the effects of 
assignment to 6 compared to 3 times per week hemodialysis on follow up RKF. In both trials, 
baseline RKF was inversely correlated with number of years since onset of ESRD. In the 
Nocturnal Trial, 63 participants had non-zero RKF at baseline (mean urine volume 0.76 l/d, urea 
clearance 2.3 ml/min, and creatinine clearance 4.7 ml/min). In those assigned to frequent nocturnal 
dialysis, these indices were all significantly lower at month 4 and were mostly so at month 12 
compared to controls. In the frequent dialysis group, urine volume had declined to zero in 52% 
and 67% of patients at months 4 and 12, respectively, compared to 18% and 36% in controls. In 
the Daily Trial, 83 patients had non-zero RKF at baseline (mean urine volume 0.43 l/d, urea 
clearance 1.2 ml/min, and creatinine clearance 2.7 ml/min). Here, treatment assignment did not 
significantly influence follow-up levels of the measured indices, although the range in baseline 
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RKF was narrower, potentially limiting power to detect differences. Thus, frequent nocturnal 
hemodialysis appears to promote a more rapid loss of RKF, the mechanism of which remains to be 
determined. Whether RKF also declines with frequent daily treatment could not be determined.
Introduction
The goal of the Frequent Hemodialysis Network (FHN) Trials was to evaluate the safety and 
efficacy of 6 times per week Nocturnal (home) or Daily (in-center) hemodialysis versus 
conventional (3 times per week) hemodialysis on an array of intermediate outcomes.1 
Challenges to enrollment and randomization,2 baseline characteristics of enrolled 
participants3 and the primary results of both trials4,5 have been published, as have selected 
secondary results focusing on mineral metabolism,6 cardiac structure,7 physical 
performance,8 nutrition and body composition.9
While residual kidney function (RKF) was not among the nine pre-specified main outcome 
domains in the FHN trials,1 there is growing interest in the effect of various dialysis 
treatments on the trajectory of RKF.10 The average estimated glomerular filtration rate 
(eGFR) of persons initiating dialysis in the United States averaged about 10 mL/min in 
recent years.11 Much of RKF is lost during the first 18 months of hemodialysis, and appears 
to depend on the primary cause(s) of kidney failure as well as other patient- and treatment-
related factors.12 Patients on peritoneal dialysis generally exhibit slower loss of RKF than do 
patients on hemodialysis,13–17 suggesting that hemodialysis-dependent factors may 
contribute.4,5 Several cohort studies have suggested that RKF is an extremely important 
determinant of mortality and morbidity in patients on either peritoneal dialysis or 
hemodialysis.12 Frequent hemodialysis theoretically could slow or hasten progressive loss of 
RKF. Frequent hemodialysis combined with increased weekly treatment times typically 
reduces the rate of ultrafiltration during hemodialysis and lowers the frequency and severity 
of intradialytic hypotensive episodes per session.4,5 Fewer episodes of intradialytic 
hypotension might reduce ischemic kidney injury and preserve RKF.12 On the other hand, 
lower blood pressures associated with more effective and complete ultrafiltration might 
reduce kidney perfusion, hastening the loss of RKF.15 A reduced need for antihypertensive 
medication18,19 may lead to discontinuation of ACE inhibitors or angiotensin receptor 
blockers. In observational studies, use of ACE inhibitors and angiotensin receptor blockers 
has been associated with preservation of RKF.14 Frequent hemodialysis may dilute the 
concentration of potentially toxic retained uremic solutes, but may also lower concentrations 
of osmotically active solutes (such as urea) that may help maintain urine flow rate and GFR.
In considering these competing potential effects, we hypothesized that frequent 
hemodialysis would result in more rapid decline in RKF, as measured by 24-hour urine 
volume (UVol), and kidney urea (Kru) and creatinine (Krcreat) clearances.
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Results
Residual Kidney Function at Baseline
Tables 1 and 2 present baseline characteristics of participants with zero Uvol (left side) and 
of participants with nonzero Uvol grouped according to randomized treatment assignment 
(right side). In the Nocturnal Trial, the 63 of 87 randomized participants with nonzero 
baseline Uvol had a mean 24-hour UVol of 0.76 L/d, Kru 2.3 mL/min, and Krcreat 4.7 mL/
min. In the Daily Trial, the 83 of 245 randomized participants with nonzero baseline UVol 
had mean UVol 0.43 L/d, Kru 1.2 mL/min, and Krcreat 2.7 mL/min.
At baseline, ESRD vintage was inversely correlated with UVol (Figure 1 and Tables 1 and 
2). In the Nocturnal Trial, mean ESRD vintage in those with zero urine output was 6.14 
years, while in those with nonzero output it was 2.42 years (Table 1). In the Daily Trial, 
ESRD vintages for zero and nonzero urine output averaged 7.37 and 2.48 years, 
respectively. Blood pressure, MRI-measured left ventricular mass, MRI-measured end-
diastolic volume (LVEDV), and bioimpedance-estimated extracellular water volume were 
not markedly different in participants without, compared to those with, urine output (Tables 
1 and 2). In those participants with urine output, baseline UVol, Kru and Krcreat were 
directly and significantly correlated; In the Nocturnal Trial, the Spearman correlation 
coefficient for UVol versus Kru was 0.69, for UVol versus Krcreat was 0.53, and for Kru 
versus Krcreat was 0.90. In the Daily Trial, analogous correlation values were: UVol versus 
Kru: 0.78; UVol versus Krcreat: 0.59; and for Kru versus Krcreat: 0.79.
Treatment characteristics and drug exposures
The distributions of achieved weekly Kt/V and weekly treatment time in the two treatment 
arms have been summarized previously.4,5 All dialyzers used in the FHN Trials, with two 
patient exceptions, were high flux, and > 95% of dialysis treatments were performed with 
membranes that were some combination of polysulfone, polyethersulfone, polyamide, 
polyarylethersulfone, or polyacrylonitrile. No more than 11% of participants used 
nonsteroidal anti-inflammatory drugs at any visit in either the Daily or Nocturnal Trials. In 
the Nocturnal Trial, the proportion of patients using ACE inhibitors or angiotensin receptor 
blockers changed from 45% to 46% in the conventional arm, and from 28% to 22% in the 
frequent arm. In the Daily Trial, the corresponding proportions decreased from 50% to 46% 
in the conventional arm and from 49% to 34% in the frequent arm.
Effects of Randomized Treatments
All analyses of the effect of the randomized treatments on RKF were restricted to the 63 
participants in the Nocturnal Trial and 83 in the Daily Trial with nonzero RKF at baseline. 
In the Nocturnal Trial, 2 of 32 participants who were randomized to frequent hemodialysis 
died and 2 additional participants underwent kidney transplantation, compared to 1 death 
and 2 transplants for 31 participants randomized to conventional dialysis. In the Daily Trial, 
2 of the 35 who were randomized to the frequent dialysis group died and 3 were 
transplanted, compared to 3 deaths and 5 transplants for 48 participants randomized to 
conventional dialysis. Several additional patients had missing RKF measurements due to 
missing or incomplete kinetic modeling information. The sample sizes for the patients with 
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nonmissing RKF measurements who were retained in the statistical analyses are displayed in 
the leftmost columns of the 4-month and 12-month portions of Tables 3 and 4.
Table 3 (Nocturnal Trial) and Table 4 (Daily Trial) display the results of the nonparametric 
intent-to-treat comparisons of the RKF outcomes between the randomized groups at months 
4 and 12 (see methods). Figures 2 and 3 display the proportions of patients with RKF 
outcomes equal to 0, and the proportions falling within the three tertiles defined by the 
baseline distribution for each RKF parameter. Values are shown at baseline and at follow-up 
months 4 and 12. In each figure, UVol is shown in panel (a), Kru is shown in panel (b), and 
Krcreat is shown in panel (c). In the Nocturnal Trial, levels of all three of these parameters, 
as well as the average of Kru and Krcreat, were significantly lower for participants assigned 
to 6 times per week hemodialysis compared to participants assigned to conventional 
hemodialysis at Month 4, with this difference largely persisting at Month 12. The percent of 
patients with UVol equal to 0 increased from 0% at baseline to 52% and 67% at months 4 
and 12, respectively, in the frequent nocturnal group, but only to 18% and 36%, 
respectively, at months 4 and 12, in the conventional hemodialysis group. In the Daily Trial, 
the levels of UVol, Kru and Krcreat were similarly distributed between the two treatment 
groups at both follow-up times.
Post hoc As-treated Analyses
In post hoc analyses, we examined the relationship between the baseline and follow-up 
values of UVol and each patient’s average number of recorded treatments and the average 
weekly treatment time. As shown in Figure 4, whereas results in the Daily Trial were 
equivocal, in the Nocturnal Trial, 1 of 16 (6%) of participants who followed a schedule of at 
least 4.5 treatments per week retained some RKF by Month 12; by contrast, 17 of 25 (68%) 
participants with fewer than 3.5 treatments retained some RKF through Month 12 
(additional details in Supplement).
Exploratory Correlational Analyses
In exploratory analyses, we examined associations of the change in UVol between baseline 
and month twelve with the change in each of several intermediate variables that might be 
considered potential mechanisms for the effect of more frequent dialysis on RKF. These 
included change in predialysis systolic or diastolic blood pressure, lowest intradialytic blood 
pressure, extracellular fluid volume, left ventricular end-diastolic volume, and osmotic load 
(as reflected by BUN). As shown in Table 5, changes in levels of each of these variables 
were not associated with change in UVol from baseline to Month 12, with one exception: in 
the 6 times per week treatment groups in both the Nocturnal Trial and Daily Trials, the 
change from baseline to early follow-up in level of minimum intradialytic systolic blood 
pressure was associated with decrease in Uvol at Month 12.
Discussion
In the FHN Nocturnal Trial, assignment to frequent hemodialysis was associated with a 
more rapid decrease in residual kidney function (RKF) whether the chosen RKF metric was 
urine volume, urea clearance, or creatinine clearance. This effect was apparent by 4 months 
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after randomization and remained evident after 12 months. In the Daily Trial, where the 
maximum allowed baseline level of RKF was lower by design (Kru <3 mL/min per 35L 
estimated body water volume), treatment assignment to frequent hemodialysis did not 
significantly influence the change in RKF.
As reviewed by Vilar and Farrington,10 RKF is associated with improved survival in 
patients on peritoneal- and hemodialysis,20–26 and also with lower hospitalization rates,27 
better nutrition, 25,28–30 less anemia and improved control of serum phosphorus.31,32 Also, 
substantial RKF has been associated with lower plasma concentrations of so-called “middle 
molecules”,33,34 better control of hypervolemia and hypertension25,35 and reduced left 
ventricular hypertrophy.36 It is therefore of some concern that despite some important 
observed benefits, participants randomized to 6-times per week hemodialysis in the 
Nocturnal Trial showed a more rapid decline in RKF compared to participants on 
conventional thrice weekly hemodialysis.
RKF may not be constant throughout the interdialytic interval. For example, Van Olden et 
al. showed that in 3 times per week hemodialysis,37 when RKF was assayed on successive 
days of the interdialytic interval, GFR progressively increased. The presumed drivers for 
this variation include the progressive increase in volume and solute load as the interdialytic 
interval progresses. In the FHN Trials, most urine collections occurred towards the end of 
interdialytic intervals. Therefore, in the participants dialyzed 3 times per week, the urine 
collection period usually did not extend for the entire interdialytic interval, while in the 
participants dialyzed 6 times per week, when urine collection was done midweek, the entire 
interdialytic interval was sampled. Thus, in the participants dialyzed 3 times per week, urine 
collections may have overestimated the average RKF relative to participants dialyzed 6 
times per week due to this sampling bias. However, when RKF drops to zero, such potential 
sampling bias is no longer an issue; in the Nocturnal Trial at 4 months, a higher fraction of 
participants randomized to 6 times per week therapy had zero RKF compared to controls. In 
those participants in whom urine output did not drop to zero, some possibility for bias still 
exists. However, a sensitivity analysis described in the Supplemental Materials suggested 
that differences in urine collection periods between the 3 and 6 times per week arm were not 
likely to be responsible for the apparent adverse treatment effect of 6 times per week 
hemodialysis on RKF.
Intradialytic hypotension has been proposed as a possible cause of accelerated loss of RKF 
with conventional hemodialysis.12 Kidneys of patients with CKD have a diminished 
capacity to autoregulate, and hence may be susceptible to ischemic damage due to transient 
drops in blood pressure during dialysis. We previously reported that in the FHN Nocturnal 
Trial, the proportion of sessions complicated by intradialytic hypotension requiring 
intervention was reduced in participants randomized to the 6 times per week dialysis,5 
suggesting that intradialytic hypotension could not be a likely explanation for more rapid 
loss of RKF; however, in both the Nocturnal and Daily Trials, the decrease from baseline to 
early follow-up in the minimum systolic blood pressure recorded during dialysis was 
associated with the decrease in urinary volume from baseline to Month 12. Therefore, a 
blood pressure-related mechanism for the accelerated fall in RKF cannot be entirely 
discounted.
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There are a number of possible reasons why RKF might decrease more rapidly with frequent 
nocturnal hemodialysis. RKF may be sustained in part by a relatively expanded extracellular 
fluid volume,38 often accompanied by hypertension.15,39 An osmotic diuresis induced by 
retained small molecular weight solutes may drive RKF and result in increased UVol. With 
frequent hemodialysis, each of these three drivers of RKF (extracellular volume, blood 
pressure, and osmotic load) may potentially be reduced. In our study, the associations 
among changes in each of these putative “mechanistic” factors and change in UVol were 
examined, and no clear cut relationships were found. The use of ACE inhibitors or 
angiotensin receptor blockers decreased slightly in the frequent dialysis arms of both trials. 
Because ACE inhibition has been associated with prolonged RKF in some studies, it is 
possible that stopping ACE inhibitors might have played a role in accelerated loss of RKF in 
some patients, but sample sizes were too small to explore this possibility.
Another possible reason for accelerated loss of RKF with frequent nocturnal hemodialysis 
concerns platelet activation and an increased inflammatory response. As blood courses 
through the extracorporeal circuit, platelet activation increases, platelet-platelet and platelet-
leukocyte aggregates form that may lodge in tissues, causing inflammatory and oxidative 
tissue damage, including to the kidneys.40 When hemodialysis is utilized 7–8 hours per 
session 6 times per week, this blood-to-circuit contact activation process is occurring up to 
48 hours per week.
Almost all patients in the two FHN trials were being dialyzed with high-flux membranes. 
The total use of “cellulosic” membranes was < 5%, and most of the cellulosic membranes 
used were cellulose triacetate, which is believe to be a relatively biocompatible surface. In 
the Nocturnal Trial, most of the patients were dialyzed at home in both arms. As described 
in Methods, an ultrafilter was used for final purification of product water, and no differences 
were found in endotoxin levels in either product water or dialysate between the two 
treatment arms.
Post hoc as-treated analyses relating UVol to the actual recorded average number of weekly 
treatments and weekly treatment time provided further evidence of a reduction in RKF with 
frequent nocturnal dialysis. In the Nocturnal Trial, all but one patient who complied with the 
more frequent dialysis prescription lost all RKF by Month 12 (Figure 4). As-treated results 
should always be interpreted with caution, as there always is a risk of selection bias; 
specifically, in this instance, patients who had lost RKF might have been more adherent with 
more frequent dialysis due to subjective clinical improvement, or greater perceived freedom 
to ingest salt and water. Nevertheless, an alternative explanation might be that frequent 
nocturnal hemodialysis as performed in the Nocturnal Trial was truly deleterious.
Might frequent hemodialysis be performed in such a way as to minimize loss of RKF? For 
example, in patients with substantial RKF, blood and dialysate flow rates could be reduced 
to avoid excessively low blood urea nitrogen concentrations. The intensity of sodium 
restriction typically recommended to patients on conventional hemodialysis could be 
somewhat liberalized, so as to avoid intradialytic or interdialytic volume depletion. One 
recent intervention in this particular direction, however, was unsuccessful, with 10 of 18 of 
patients withdrawing from the study because of adverse events.41 Techniques to minimize 
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platelet activation during dialysis might reduce this process and help preserve RKF. While 
use of more “biocompatible” synthetic membranes may reduce platelet activation,42 in the 
FHN trial, membranes largely believed to be biocompatible were used. Studies to examine 
the effect of “anti-platelet-activating” drugs on RKF may also be of interest.
While more frequent hemodialysis may hasten the fall in RKF, other salutary effects of 
frequent hemodialysis could counterbalance this effect. Although mortality and 
hospitalization outcomes have not yet been assessed in adequately powered randomized 
controlled trials, frequent nocturnal hemodialysis per se has been shown to lower plasma 
levels of beta-2-microglobulin, protein-bound toxins, and phosphorus. Frequent nocturnal 
hemodialysis also has been reported to result in partial correction of left ventricular 
hypertrophy,18,19,43,44 although results from several trials including the FHN Nocturnal 
Trial, are mixed.
This study has several strengths. First, results were derived from two randomized clinical 
trials. Second, we objectively assessed RKF using three complementary and well validated 
metrics, UVol, Kru and Krcreat. Third, while the trial populations were selected, there was 
broad representation by age, sex, race/ethnicity, ESRD vintage and primary cause of kidney 
disease.2,3 This study also has several limitations. The design of the Daily Trial was not 
conducive to addressing the question of whether 6 times per week therapy reduced RKF in a 
similar fashion to what we observed for nocturnal dialysis. A large fraction of participants in 
the Daily Trial had zero UVol and could not be assessed for change over time. Moreover, 
the range of RKF (as gauged by Kru) was narrow, as patients with Kru >3 mL/min/35L 
estimated body water were excluded from participation. Thus, while the Daily Trial reached 
98% of its recruitment target, its power to detect a treatment-related change in RKF was 
limited. Although the Nocturnal Trial had more difficulty in recruitment, a much larger 
fraction of participants had nonzero UVol, and could be assessed for changes in UVol, Kru 
and Krcreat. Finally, the study was not blinded (due to the nature of the intervention). Since 
participants were not directly observed during their timed urine collections, the 
completeness of collection may have been influenced by the group to which each subject 
was randomized.
In summary, frequent nocturnal hemodialysis appears to accelerate loss of RKF. We were 
unable to properly evaluate whether a similar adverse effect on RKF occurs with the more 
commonly prescribed “short daily” dialysis type of schedule that was used in the Daily 
Trial. Given the strong associations among RKF, mortality and morbidity in peritoneal and 
hemodialysis cohorts, the potential for more rapid loss of RKF should be considered when 
balancing the risks and benefits of frequent hemodialysis in individual patients.
Methods
The Frequent Hemodialysis Network (FHN) Daily Trial was a multi-center, prospective, 
randomized, parallel-group trial of frequent (6 times per week), as compared with 
conventional (3 times per week) in-center hemodialysis.1 The FHN Nocturnal Trial was a 
similarly designed trial comparing the effects of frequent (6 times per week) with 
conventional (3 times per week) nocturnal hemodialysis.1 The majority of participants in the 
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Nocturnal Trial were receiving hemodialysis at home, with only the 6 times per week 
participants receiving hemodialysis at night. Detailed description of study designs have been 
previously described.1
Subjects on maintenance hemodialysis needed to achieve a mean equilibrated Kt/Vurea >1.0 
for the last two baseline hemodialysis sessions. Major exclusion criteria included age <13 
(Daily) or <18 (Nocturnal) years, KrU >3 mL/min/35L (Daily) or residual GFR (mean of 
creatinine and urea clearance) >10 mL/min/1.73m2 (Nocturnal), life expectancy <6 months, 
medical need for hemodialysis >3 times per week, history of poor adherence to 
hemodialysis, and anticipated kidney transplant or relocation within 12 months. Informed 
consent was obtained from each subject. The trials were approved by the Institutional 
Review Board at each participating study site and conducted in full accordance with the 
Declaration of Helsinki.
After randomization in the Nocturnal Trial, participants were assigned to either 3 times per 
week hemodialysis to a prescribed standard Kt/Vurea of >2.0 and a session length of ≥ 2.5 
hours or 6 times per week hemodialysis to a standard Kt/Vurea of ≥ 4.0 for ≥ 6 hours per 
session. After randomization in the Daily Trial, participants who were assigned to 
hemodialysis 6 times per week (n=125) had a target equilibrated Kt/Vn (where 
Vn=3.271×V2/3) of 0.9 provided that the length of the session was between 1.5 and 2.75 
hours.21 Subjects who were assigned to 3 times per week hemodialysis continued their usual 
hemodialysis prescriptions, which included a minimum target equilibrated Kt/Vurea of 1.1 
and a session length of 2.5 to 4.0 hours.
All laboratory measurements were performed by local laboratories. Blood was drawn either 
as serum or plasma, centrifuged, and then the refrigerated sample was sent to the local 
laboratory for analysis within 24 hours. Bioimpedance measurements (midweek, predialysis) 
were performed by study coordinators trained in the use of the device.9 Measurements of 
resistance and reactance were done with a single-frequency (50 kHz) wrist-to-ankle 
bioimpedance analysis device (RJL Systems, Clinton Township, MI, USA). Extracellular 
volume was calculated as the difference between total body water45 and intracellular 
volume.46
Timed 24 hour urine collections were performed during the interdialytic intervals preceding 
kinetic modeling sessions for patients producing at least 80 ml of urine/24 hrs at baseline, 
Month 4 and Month 12 of follow-up (additional details in Supplemental materials). For each 
of these kinetic modeling sessions a 2-pool urea kinetic model was fit to estimate the 
patient’s 2-pool urea volume (Vdp) based on the pre and post dialysis BUNs, the dialyzer 
clearance computed from blood flow, dialysate flow and dialyzer K0A, and the patient’s 
recorded treatment schedule of the week preceding the modeling session. The Runge-Kutta 
algorithm was used to estimate the patient’s BUN vs. time concentration curve over the full 
week, including the time period during which the urine collection was performed. An 
intercompartmental urea clearance (Kc, ml/min) of 0.016 × Vdp (Vdp = 2-pool urea 
distribution volume in mL) was assumed to account for post-dialysis rebound. The estimated 
Vdp was then used as an input parameter in to fit an analogous 2-pool kinetic model to the 
pre- and post-dialysis serum creatinine concentration, solving for the dialyzer clearance of 
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creatinine and the creatinine vs. time concentration curve over the same week. A creatinine 
Kc of 0.010 × Vdp was assumed. Finally, residual urea and creatinine clearances were 
estimated as the excretion rate of each solute divided by the time-averaged serum 
concentration of each solute during the collection period. The latter was estimated from the 
weekly serum urea and creatinine profiles generated by 2-pool kinetic modeling.
In two cases, missing post-dialysis BUNs or post-dialysis creatinine were imputed by 
multiplying the pre-dialysis BUNs and pre-dialysis creatinines by the average post vs. 
predialysis BUN or creatinine ratios from neighboring kinetic modeling sessions 1 month 
prior to and 1 month after the kinetic modeling session with the residual urine collection. In 
4 other cases in which urine collections were performed outside of the week prior to the 
kinetic modeling session, the time averaged urea and creatinine concentrations were imputed 
by treating the collection as though it occurred in the interdialytic interval preceding the 
kinetic modeling session, with the same time between the collection and the initiation of the 
kinetic modeling session as the time between the collection and the subsequent dialysis after 
the after urine collection. Residual GFR (in ml/min) was estimated as the average of the 
residual urea and creatinine clearances.
Data Analyses
Baseline characteristics were summarized as frequency and percent for categorical variables 
and as means and standard deviations for continuous variables, with patients grouped into 
those with 0 RKF (operationally defined as those producing < 80 ml of urine volume/24 hr), 
and those with nonzero RKF. Scatter plots with local regression curves were used to relate 
UVol to ESRD vintage at baseline.
Prior to examination of outcome data, the study investigators designated UVol as the main 
secondary outcome for the RKF domain, while residual urea clearance, residual creatinine 
clearance, and residual GFR were designated as additional secondary outcomes. All 
outcome analyses were restricted to patients with non-zero RKF at baseline. The main 
intent-to-treat analyses compared the 4-month and 12-month values of each of the four RKF 
outcomes between the randomized treatment groups using a nonparametric Wilcoxon rank 
sums test, with stratification by the tertiles of the baseline level of the outcome being 
analyzed. The Van Elteren version47 of the stratified Wilcoxon test was used as 
implemented in the FREQ procedure of SAS. Results of the intent-to-treat comparisons of 
each of the above outcomes were also graphically displayed at months 4 and 12 by stacked 
bar-charts, showing the % of patients with 0 RKF and the % falling within each of the three 
tertiles of the baseline level of the RKF outcome. Sensitivity analyses were performed to 
investigate the dependence of the study results on differences in the timing of the urine 
collections in the interdialytic intervals between the study groups (see Supplementary 
Materials).
We also displayed the relationship of the changes in UVol from baseline to months 4 and 12 
with the average number of recorded treatments per week and with the average recorded 
weekly treatment time over the preceding follow-up months. Spearman correlations were 
used to summarize the association of changes in UVol from baseline to 12 months with 
changes in other parameters.
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All analyses were performed without formal adjustment for multiple comparisons using SAS 
version 9.2. Two-tailed P -values <0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Regression analysis of baseline urine volume as a function of ESRD vintage for the 
Nocturnal and Daily Trials. The drawn curves were fit using locally weighted least squares 
regression. The Spearman correlations between vintage and baseline urine volume were 
−0.49 (p < 0.0001) in the Daily Trial, and −0.53 (p < 0.0001) in the Nocturnal Trial.
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Figure 2. 
Nocturnal Trial Subjects with Baseline Nonzero Urine Volume: Time course in level of 
residual kidney function measured as (a) UVol; (b) Kru; or (c) Krcreat, at baseline, Month 4 
and Month 12. The bar graphs depict the proportions of patients falling into the different 
categories and are provided to describe the outcome distribution. The bar graph ranges 
represent baseline tertiles (of those with nonzero function at baseline) for each variable. See 
Table 3 for P -values of nonparametric tests comparing the RKF parameters between 
treatment groups.
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Figure 3. 
Daily Trial Subjects with Baseline Nonzero Urine Volume: Time course in level of residual 
kidney function measured as (a) UVol; (b) Kru; or (c) Krcreat, at baseline, Month 4 and 
Month 12. The bar graphs depict the proportions of patients falling into the different 
categories and are provided to describe the outcome distribution. The bar graph ranges 
represent baseline tertiles (of those with nonzero function at baseline) for each variable. See 
Table 4 for P -values of nonparametric tests comparing the RKF parameters between 
treatment groups.
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Figure 4. 
Baseline and 12-month urine volumes in both trials as a function of average frequency (left 
panels) and average weekly dialysis times (right panels). Only those participants with 
nonzero urine volume at baseline were included. The solid circles represent 12-month urine 
volume for participants randomized to the frequent arm and open circles indicate 12-month 
urine volume for participants randomized to the control arm. Values of some of the points 
were shifted laterally slightly to reduce overlap between plot symbols. The endpoint of each 
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vertical line linking to each circle depicts the baseline urine volume level for that particular 
subject.
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Table 5
Change in Urinary Volume from Baseline to Month 12 vs. Change in Hypothesized Mediating Factors from 
Baseline to Month 12
Spearman R
3X P-value
Spearman R
6X P-value
Nocturnal Trial
ΔPredialysis Systolic BP (mmHg) −0.20 0.38 0.02 0.94
ΔPredialysis Diastolic BP (mmHg) 0.21 0.34 0.11 0.60
ΔLowest Intradialytic Systolic BP
(mmHg)
0.07 0.76 0.77 0.00
ΔPredialysis BUN (mg/dL) −0.06 0.78 −0.07 0.74
ΔBIA Extracellular Water (L) −0.43 0.06 −0.12 0.59
ΔLVEDV (ml) −0.20 0.36 0.03 0.90
ΔTotal Uf per session (L) −0.15 0.50 −0.36 0.09
Daily Trial
ΔPredialysis Systolic BP (mmHg) 0.09 0.61 0.45 0.02
ΔPredialysis Diastolic BP (mmHg) 0.12 0.51 0.33 0.11
ΔLowest Intradialytic Systolic BP
(mmHg)
0.06 0.73 0.39 0.05
ΔPredialysis BUN (mg/dL) 0.15 0.42 0.00 0.99
ΔBIA Extracellular Water (L) −0.21 0.26 0.02 0.93
ΔLVEDV (ml) 0.05 0.80 0.30 0.15
ΔTotal Uf per session (L) −0.44 0.01 −0.29 0.16
3x = subjects randomized to receive conventional 3 times per week dialysis treatments; 6x = subjects randomized to 6 times per week dialysis 
treatments. Only patients with nonzero urine volume at baseline were included in this analysis.
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